Brain Morphometry and FMS Symptoms

Brain morphometry and FMS symptoms SUPPLEMENTARY MATERIAL

SUPPLEMENTARY MATERIAL

THE IMPACT OF FIBROMYALGIA SYMPTOMS ON BRAIN MORPHOMETRY

Carolina Diaz-Piedraa,b, Manuel A. Guzmanc, Gualberto Buela-Casala, & Andres Catenaa Brain Imaging and Behavior Corresponding author: [email protected]

aMind, Brain, and Behavior Research Center-CIMCYC; University of Granada; Campus de Cartuja s/n; 18071 Granada; Spain bCollege of Nursing & Health Innovation; Arizona State University; 550 N. 3rd St.; 85004 Phoenix, AZ, USA cService of Rheumatology; University Hospital Virgen de las Nieves; Avda. de las Fuerzas Armadas 2; 18014 Granada; Spain

1. CLINICAL DATA

Supplemental Table 1 Descriptive statistics for pain intensity, psychological distress, anxiety, depression, sleep- related, and health-status measures of patients with fibromyalgia syndrome and healthy controls.

Fibromyalgia patients Healthy controls N=23 N=23 Mean (SD) Mean (SD) Pain intensity* 6.1 (1.9) 0.9 (1.3) Psychological distress: HADS* 20.3 (7.2) 9.9 (6.1) Anxiety: STAI-T* 34.7 (11.4) 18.4 (10.9) Anxiety: STAI-S* 24.9 (11.4) 13.7 (8.8) Depression: BDI* 24.7 (12.2) 6.4 (7.2) Sleep quality: PSQI* 14.2 (3.9) 3.6 (2.3) Diurnal sleepiness: ESS* 10.9 (5.9) 5.0 (3.8) Health status: FIQ* 63.5 (15.3) 6.9 (7.4) Note. SD = Standard deviation; HADS = Hospital Anxiety and Depression Scale; STAI = State-Trait Anxiety Inventory; PSQI = Pittsburgh Sleep Quality Index; ESS = Epworth Sleepiness Scale; FIQ = Fibromyalgia Impact Questionnaire. * p<.05 Brain morphometry and FMS symptoms SUPPLEMENTARY MATERIAL

2. COMPARISON OF LOCAL BRAIN VOLUMES BETWEEN FMS PATIENTS AND HEALTHY CONTROLS

FMS patients exhibited less gray matter volume (GMV) in the left medial and superior orbital frontal gyrus (BA11) and greater GMV in the temporal pole (BA38) (corrected p-values<.05). No differences in local WMV were observed between groups (all corrected p-values>.05).

Supplemental Table 2 Local gray matter volume differences in patients with fibromyalgia syndrome (N=23) relative to healthy controls (N=23).

Effect Lobe Area BA k T x y z FMS < Controls Frontal L Frontal Med/Sup Orb 11 469 5.22 -17 53 -24 FMS > Controls Frontal L Temporal Pole 38 542 4.49 -53 15 -29 Note. FMS=Fibromyalgia syndrome; L=Left; Med=Medial; Sup=Superior; Orb=Orbital; BA=Brodmann area; k=number of voxels; T=Peak t values; x, y, z= Montreal Neurological Institute coordinates (in mm).

Supplemental Fig 1 Coronal, sagittal, and axial brain slices showing the areas exhibiting significant gray matter volume (GMV) differences between fibromyalgia syndrome (FMS) patients (N=23) and healthy controls (N=23) (corrected p<.05), superimposed on a high-resolution T1-weighted template (generated by averaging 46 scans). Brain morphometry and FMS symptoms SUPPLEMENTARY MATERIAL

Areas with reduced GMV in FMS vs. healthy controls are shown in blue; areas with increased GMV in FMS vs. healthy controls are shown in red. Coordinates are shown in Supplemental Table 2.